Gland Pharma Ratios

Gland Pharma Ltd Ratios

The Gland Pharma Ltd Ratios page provides a complete fundamental analysis of Gland Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Gland Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Gland Pharma Ltd (NSE: GLAND, BSE: 543245) is currently trading at ₹1780.80, with a market capitalization of ₹293.21B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Gland Pharma Ltd remains a key stock for fundamental analysis using Gland Pharma Ltd Ratios.

Gland Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Gland Pharma Ltd P/E ratio currently stands at 37.55, making it one of the most tracked metrics in Gland Pharma Ltd Ratios.

Historically, the Gland Pharma Ltd P/E ratio has shown strong fluctuations:

• 2024: 37.55
• 2023: 39.28
• 2022: 26.75
• 2021: 44.39
• 2020: 39.34

The decline in Gland Pharma Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Gland Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.87.

Historical P/B trend:

• 2024: 2.87
• 2023: 3.48
• 2022: 2.63
• 2021: 7.50

Gland Pharma Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Gland Pharma Ltd P/S ratio currently stands at 4.69, an important part of Gland Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 4.69
• 2023: 5.38
• 2022: 5.79
• 2021: 12.27

A stable or declining Gland Pharma Ltd P/S ratio indicates cautious market sentiment.

Gland Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Gland Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 25.21.

Historical Gland Pharma Ltd Price to Cash Flow Ratio:

• 2024: 25.21
• 2023: 27.38
• 2022: 40.30
• 2021: 58.58
• 2020: 59.01

The declining Gland Pharma Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Gland Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Gland Pharma Ltd EV currently stands at ₹235.92B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 235.92B
• 2023: 288.75B
• 2022: 171.25B
• 2021: 505.46B

Gland Pharma Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Gland Pharma Ltd EV/EBITDA ratio is currently 18.45, a key metric in Gland Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 18.45
• 2023: 21.62
• 2022: 16.55
• 2021: 33.39

Stable Gland Pharma Ltd EV/EBITDA indicates balanced valuation.

Gland Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Gland Pharma Ltd D/E ratio is currently 0.03, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.03
• 2023: 0.04
• 2022: 0
• 2021: 0

Gland Pharma Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Gland Pharma Ltd ROE currently stands at 7.82%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 7.82
• 2023: 9.26
• 2022: 10.33
• 2021: 18.55

Declining ROE indicates pressure on profitability.

Gland Pharma Ltd Ratios Analysis Summary

The Gland Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Gland Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Gland Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.